Culture

Magazine

Indie Film ‘Debbie and Doug Drop Acid in the Desert’ is a Visual and Emotional Trip

‘Debbie and Doug Drop Acid in the Desert’ director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.

Magazine

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

Magazine

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Magazine

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Magazine

Ayahuasca Healings’ Trinity de Guzman calls coronavirus “a necessary purge”

“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.

Magazine

Native American Churches Request that Peyote Not Be Included in Decriminalization Initiatives

A long-fought battle for access to peyote, and a dwindling population in the United States has led Native American Church members and peyote conservationists to request that peyote be left out of decriminalization efforts.

Magazine

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Magazine

Talking Psychedelic Capitalism in a WeWork Ballroom

Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

Magazine

Christian Angermayer’s ATAI Life Sciences is positioned to take the psychedelic throne from MAPS

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

Magazine

“Making psychedelics boring again”— Unless you’re a privileged psychedelic executive, of course

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Magazine

Psychedelic Trade Secrets and Get-Rich-Quick Schemes —a Benefit to Investors, a Harm to Progress

“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Magazine

Never Forget: Before There Was A Mush Rush, There Was A Plea For Decency

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?